Nexalin Technology Inc NXL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Nexalin Technology Announces Fourth Peer-Reviewed Publication in Alzheimer's Disease: 15 mA DIFS™ Significantly Improves Sleep Quality in Patients with Mild Alzheimer's Disease
Nexalin Technology Regains Compliance with Nasdaq Minimum Bid Price Requirement; Nasdaq Hearings Panel Grants Request for Continued Listing
Nexalin Technology Signs Definitive Exclusive Distribution and Local Manufacturing Agreement for Brazil and South America, Marking a Major Step in its Transition Toward Commercial Revenue Generation
Nexalin Technology Taps Neuromodulation Commercial Executive Robert DiTota to Advise on its Global Commercialization Strategy
Anixa Biosciences and Nexalin Technology Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV
Nexalin Technology Announces New Secondary Analysis of Previously Published Clinical Trial Data Reveals Previously Unreported Improvements in Memory, Comprehension and Language Function in Alzheimer’s Patients; ADAS-Cog Subscale Analysis to Guide Design of Planned U.S. Alzheimer’s Pilot Study
Nexalin Technology Announces Reverse Stock Split
Trading Information
- Previous Close Price
- $1.40
- Day Range
- $1.42–1.50
- 52-Week Range
- $1.31–40.80
- Bid/Ask
- $1.41 / $1.50
- Shares Outstanding
- 1.05M
- Market Cap
- $1.50M
- Volume/Avg
- 1,614 / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 4.16
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Nexalin Technology Inc designs and develops neurostimulation products and bioelectronic medical technology to treat anxiety and insomnia without drugs or psychotherapy. The Company has developed the Generation 1 (Gen 1) medical device, a cranial electrotherapy stimulation (CES) device classified by the U.S. Food and Drug Administration (FDA) as a Class II device. The Company operates as a single operating and reportable segment, focused on the design and development of innovative neurostimulation products. The Company focuses on treating mental health conditions without reliance on drugs or psychotherapy. Geographically, it generates sales in the USA and China, with China generating the maximum sales.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Value
- Total Number of Employees
- 8
- Website
- https://www.nexalin.com
Valuation
Metric | NXL |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.68 |
Price/Sales | 4.16 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | NXL |
|---|---|
Quick Ratio | 0.71 |
Current Ratio | 1.25 |
Interest Coverage | — |
Quick Ratio
NXL
Profitability
Metric | NXL |
|---|---|
Return on Assets (Normalized) | −136.62% |
Return on Equity (Normalized) | −166.56% |
Return on Invested Capital (Normalized) | −166.62% |
Return on Assets
NXL
Medical Devices Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Abbott Laboratories ABT | LOCK|!z@%?Mr | LOCK|^fPt | $197B | |||
| Medtronic PLC MDT | LOCK|?!<#^?$ | LOCK|jVtN | $134B | |||
| Stryker Corp SYK | LOCK|^WLdZXC | LOCK|%C | $128B | |||
| Boston Scientific Corp BSX | LOCK|%XsZZ>? | LOCK|S!vmy | $65B | |||
| Edwards Lifesciences Corp EW | LOCK|l!T&Wt%S | LOCK|^sM$ | $58B | |||
| GE HealthCare Technologies Inc Common Stock GEHC | LOCK|plNVRY | LOCK|N#F | $38B | |||
| DexCom Inc DXCM | LOCK|<>g$s^<> | LOCK|rDvG< | $31B | |||
| Koninklijke Philips NV ADR PHG | LOCK|!P# | LOCK|n@ | $30B | |||
| Steris PLC STE | LOCK|z?nW@M | LOCK|Gp@KM | $25B | |||
| Zimmer Biomet Holdings Inc ZBH | LOCK|Y#%zlN>l | LOCK|#CM | $20B |
United States